Lupus nephritis is kidney inflammation caused by lupus, an autoimmune disease. It's a serious complication of lupus. The kidneys are damaged, which can lead to problems like high blood pressure and kidney failure if not treated properly.
Every report comes from a Lived member, sent anonymously.
Have you tried Mycophenolic Acid for Lupus Nephritis?
Lupus nephritis is kidney inflammation caused by systemic lupus erythematosus (SLE, usually just called lupus). Lupus is an autoimmune disease: the immune system mistakenly attacks the body's own tissues. When that attack reaches the kidneys, it inflames the tiny filters that clean the blood and make urine. Inflamed filters leak protein and blood into the urine, and if the inflammation goes on long enough, they can scar. Scarring is permanent, so lupus nephritis is one of the most important parts of lupus to find and treat early. Kidney involvement is common. It develops at some point in roughly 20 to 60 percent of people with lupus, and it is more frequent and often more aggressive in children with lupus than in adults. Possible signs include foamy urine, swelling in the legs, feet or ankles (sometimes the hands or face), and high blood pressure. Many people notice little or nothing at first, and the problem shows up on urine and blood tests. With treatment, many people keep good kidney function, but some lose function over time, and roughly 1 in 10 eventually reaches kidney failure and needs dialysis or a transplant.
Lupus nephritis happens only in people who have lupus. The kidney damage comes from the immune system itself: immune cells and antibodies made against the body's own material settle in and attack kidney tissue. Why lupus develops in the first place is not fully known. Researchers think genetics, immune system differences and environmental factors (such as certain viral infections, sunlight, some medicines and smoking) play a part, but none of these is a proven cause of kidney involvement in a particular person. Some groups are more likely to develop kidney disease once they have lupus. Lupus itself is far more common in women, but men with lupus are more likely to have kidney involvement. Black, Hispanic or Latino, and Asian American people are more likely than white Americans to develop lupus nephritis, and children with lupus are more likely to have it than adults. In people of African ancestry, high-risk versions of a gene called APOL1 are linked to a higher chance that lupus nephritis progresses to kidney failure. These are differences in risk, not something a person caused or could have prevented.
Because early lupus nephritis is easy to miss, people with lupus have their urine and blood pressure checked regularly. A urine dipstick looks for protein and blood, and the urine is examined under a microscope for cells and casts (clumps of cells shaped by the kidney's tubes), which point to active inflammation. A urine protein-to-creatinine ratio (UPCR) uses a single sample to estimate how much protein is lost over a day. Healthy kidneys let very little protein through, so a rising ratio is a warning sign, and a falling one shows treatment is working. Blood tests measure creatinine, a waste product the kidneys clear, which is used to calculate the estimated glomerular filtration rate (eGFR): roughly how well the kidneys are filtering. An eGFR of 60 or more is in the normal range, a value below 60 may mean kidney disease, and 15 or below is kidney failure. A normal eGFR does not rule out lupus nephritis, because active inflammation often leaks protein before filtering falls, which is why urine protein is followed as well. Doctors also follow complement proteins and anti-double-stranded DNA (anti-dsDNA) antibodies, blood markers that often change when lupus is active. The test that settles the diagnosis is a kidney biopsy, in which a thin needle guided by ultrasound or a computed tomography (CT) scan removes a small piece of kidney under local anesthetic and light sedation. A biopsy is usually recommended when tests suggest lupus is affecting the kidneys, because urine protein alone can mislead: serious inflammation can be present with only modest protein loss. The pathologist assigns a class from I to VI. Classes III and IV (proliferative nephritis) are the most inflammatory and need the strongest treatment, class V (membranous nephritis) mainly causes protein leakage, and class VI means advanced scarring. The report also grades how much active inflammation and how much scarring is present, which shapes treatment and outlook.
Treatment aims to calm the immune attack quickly, protect the kidneys from scarring and keep the disease quiet for the long term. For active proliferative nephritis, current guidelines combine a corticosteroid (often an intravenous pulse of methylprednisolone followed by prednisone tablets that are tapered down) with other immunosuppressive medicines. The usual backbone is mycophenolate, an oral immunosuppressant, or low-dose intravenous cyclophosphamide, a stronger drug given in a limited course. The 2024 US guideline usually adds a third medicine from the start, while other guidelines also accept two-drug combinations. Belimumab (Benlysta) is an antibody given by infusion or injection that dampens antibody-producing B cells. Voclosporin (Lupkynis) is an oral immunosuppressant of a different type that can lower urine protein quickly in people whose kidney function is still reasonably good. Obinutuzumab (Gazyva) is an infusion that removes B cells. The choice depends on the biopsy class, kidney function, pregnancy plans, side effects and access. These medicines work by suppressing part of the immune system, so the main trade-off is a higher risk of infection, which is why vaccinations and infection checks are part of care. Steroids work fast, but long-term exposure adds up to bone fractures, heart disease and cataracts, so doctors aim to taper them to a low dose within months. Cyclophosphamide can harm fertility, which is one reason mycophenolate is often preferred for people who want children. Mycophenolate itself causes miscarriage and birth defects, so pregnancy needs to be planned with the care team, and mycophenolate and some blood pressure medicines switched beforehand. Treatment is long. After a good response, guidelines recommend continuing immunosuppression for about 3 to 5 years to prevent relapse. Alongside it, most people take hydroxychloroquine, a long-standing lupus medicine that is linked to better survival and less long-term organ damage. Blood pressure control matters, often with an angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB), blood pressure medicines that also reduce protein leakage. A lower-sodium diet, cholesterol management and, for some, advice from a kidney dietitian round out care.
Lupus nephritis is usually managed for years rather than cured in one course. The first months are the most intensive, with frequent visits, infusions or new tablets, and blood and urine tests to see whether protein in the urine is falling. An early drop is one of the best signs that kidney function will hold up over the long term. Improvement is gradual, and some people need a change of medicine if their numbers stall. Response is not guaranteed: even with standard treatment, a substantial share of people do not reach full remission at first. Once the disease is under control, visits become less frequent, but regular urine and blood tests continue because flares can return even after a long quiet period, and tests often catch them before they cause obvious problems. Care is usually shared between a rheumatologist and a nephrologist (kidney specialist). Living with long-term immunosuppression means paying attention to infections, keeping vaccinations current and taking medicines consistently, which is part of preventing relapse. For people who may become pregnant, pregnancy is best timed for a period when the disease has been quiet and medicines have been adjusted, because lupus nephritis raises the risk of flares, preeclampsia (dangerously high blood pressure in pregnancy) and other complications. If kidney function declines to failure despite treatment, dialysis and kidney transplantation are established options.
If you have lupus, keep to your scheduled urine and blood tests even when you feel well, and ask whether your kidneys are being checked. If you might become pregnant, or are pregnant, talk with your care team as early as possible so medicines can be reviewed. Contact your care team without waiting for the next visit if you notice foamy urine, new swelling in your legs, feet, ankles or face, or home blood pressure readings that are higher than usual. While taking immunosuppressive medicines, also call if you develop fever, chills or sweats, a cough or flu-like illness, or a warm, red, painful area of skin, since infections can become serious more quickly. Contact your care team the same day if you are passing much less urine than usual. Get emergency care (call 911) for a very high blood pressure reading together with chest pain, shortness of breath, weakness or numbness, vision changes, trouble speaking, or a severe headache with confusion, and for sudden trouble breathing, which can mean fluid is building up in the lungs.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share what living with Lupus Nephritis is like, what's helped you, or ask the community a question.